<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04576858</url>
  </required_header>
  <id_info>
    <org_study_id>CURE</org_study_id>
    <nct_id>NCT04576858</nct_id>
  </id_info>
  <brief_title>Clinical Utility of Circulating Tumor DNA in Gastro-Esophageal Cancer</brief_title>
  <acronym>CURE</acronym>
  <official_title>Clinical Utility of Circulating Tumor DNA in Gastro-Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective cohort study designed to evaluate the treatment effect as well as&#xD;
      predictive and prognostic factors with special emphasis on the clinical utility of ctDNA in&#xD;
      plasma in patients with gastroesophageal cancer. Patients with gastroesophageal cancer are&#xD;
      included in 5 separate cohorts scheduled for&#xD;
&#xD;
        -  Surgical resection + perioperative chemotherapy (cohort 1)&#xD;
&#xD;
        -  Neoadjuvant chemoradiotherapy followed by surgical resection (cohort 2)&#xD;
&#xD;
        -  Definitive chemoradiotherapy with curative intent (cohort 3)&#xD;
&#xD;
        -  Systemic therapy with the intent to prolong survival (cohort 4)&#xD;
&#xD;
        -  Palliative treatment without the use of chemotherapy (cohort 5)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate RECIST 1.1</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration RECIST 1.1</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">1950</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Surgical resection + perioperative chemotherapy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Neoadjuvant chemoradiotherapy followed by surgery</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Definitive chemoradiotherapy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Chemotherapy with the aim to prolong life expectancy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: Non-chemotherapeutic palliation</arm_group_label>
    <description>E.g. Palliative radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Circulating tumor DNA</intervention_name>
    <description>Measurement of circulating tumor DNA from plasma over a period of 2 years.</description>
    <arm_group_label>Cohort 1: Surgical resection + perioperative chemotherapy</arm_group_label>
    <arm_group_label>Cohort 2: Neoadjuvant chemoradiotherapy followed by surgery</arm_group_label>
    <arm_group_label>Cohort 3: Definitive chemoradiotherapy</arm_group_label>
    <arm_group_label>Cohort 4: Chemotherapy with the aim to prolong life expectancy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes patients with gastroesophageal cancer in five prospective&#xD;
        cohorts. Neither WGS/WES on primary tumor nor serial blood samples for ctDNA are mandatory&#xD;
        for inclusion in the study. However, it is highly encouraged to perform WGS/WES of the&#xD;
        primary tumor. A retrospective cohort will be open for inclusion to facilitate initial&#xD;
        hypothesis testing to be validated in the prospective cohorts&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Gastroesophageal cancer Age 18 years or older Able to understand and sign written informed&#xD;
        consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients not providing informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Morten Mau-Sørensen, MD, PhD</last_name>
    <phone>35450879</phone>
    <phone_ext>0045</phone_ext>
    <email>mms@rh.regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Mau-Sørensen, MD, PhD</last_name>
      <phone>35450879</phone>
      <phone_ext>0045</phone_ext>
      <email>morten.mau-soerensen@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Lene Baeksgaard</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Achiam</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rajendra S Garbyal</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olga Oestrup</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mette Siemsen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Morten Thorsteinsson</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camilla Qvortrup</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jane P Hasselby</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lise B Ahlborn</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Morten Mau-Sørensen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 23, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2020</study_first_posted>
  <last_update_submitted>September 30, 2020</last_update_submitted>
  <last_update_submitted_qc>September 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Morten Mau-Sørensen</investigator_full_name>
    <investigator_title>Chief Physician, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Circulating Tumor DNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

